K-911 phase 3 long-term study

Phase 3 long-term study of K-911 (bimatoprost grenod) in patients with primary open-angle glaucoma (broad definition), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2051250049

Enrollment

120

Registered

2025-06-20

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POAG(broad definition), exfoliation glaucoma, pigmentary glaucoma, OH

Interventions

K-911 ophthalmic solution 0.1% administered topically When using a beta-blocker, beta-blocker ophthalmic solution administered topically

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with POAG (board definition) , exfoliation glaucoma, pigmentary glaucoma or OH

Exclusion criteria

Exclusion criteria: (1)Patients in whom the best-corrected visual acuity is <0.3 (2)Patients who are expected to undergo the following treatments during the study period. 1)Use of anti-glaucoma/anti-OH drugs(excluding for beta-blockers used in accordance with regulations.) 2)Use of contact lenses.

Design outcomes

Primary

Measure	Time frame
Efficacy:Changes from baseline in intraocular pressure after 2 week (at 16:00) Safety:Presence or absence of adverse events and side effects	—

Secondary

Measure	Time frame
Efficacy Percent changes from baseline in intraocular pressure after 2 week (at 16:00)	—

Contacts

Public ContactContact for clinical trial information

Kowa Company, Ltd.

ctrdinfo@kowa.co.jp+81-3-3279-7454

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026